Form 4: Minerva Neurosciences Director Granted Performance Options

Minerva Neurosciences Director Inderjit Kaul was granted 364,504 stock options with vesting tied to clinical trial milestones.

Summary

• Inderjit Kaul, a Director of Minerva Neurosciences, Inc. (NERV), was granted 364,504 stock options.
• The options have an exercise price of $3.98 per share and are set to expire on December 21, 2035.
• Vesting of the options is conditional: 25% vests on November 14, 2026.
• An additional 45% vests on the tenth day following the public announcement of statistically significant primary endpoint achievement in the Phase 3 confirmatory trial of roluperidone in schizophrenia (12-week timepoint).
• The remaining 30% vests on the tenth day following the public announcement of safety data from the 40-week relapse assessment phase.
• All vesting is contingent on Mr. Kaul providing services under a consulting agreement dated November 14, 2025, on each vesting date.

Sentiment

Score: 7

Explanation: The grant of stock options to a director, with vesting tied to key clinical trial milestones, aligns the director's interests with the company's strategic objectives and potential future success. However, the inherent risks of clinical trials introduce uncertainty regarding the ultimate value and vesting of these options.

Positives

• The grant of stock options to Director Inderjit Kaul directly aligns his financial interests with the company's strategic success, particularly the critical Phase 3 trial for roluperidone.
• The performance-based vesting structure incentivizes the director to contribute to the successful achievement of key clinical milestones, which could benefit shareholders.
• The options have a long expiration date of December 21, 2035, providing ample time for the company to achieve its clinical and potential commercial objectives.

Negatives

• A significant portion (75%) of the options' vesting is contingent on the successful outcome and public announcement of specific results from the Phase 3 trial of roluperidone, introducing substantial performance risk.
• The value of the options is entirely dependent on the future stock price exceeding the $3.98 exercise price, which is not guaranteed and subject to market fluctuations and clinical trial outcomes.

Risks

• Clinical Trial Risk: The primary risk is the potential failure of the Phase 3 confirmatory trial of roluperidone in schizophrenia to achieve its primary endpoint on a statistically significant basis, or the failure to demonstrate acceptable safety data. Such outcomes would prevent 75% of the options from vesting and could significantly negatively impact the company's stock price and future prospects.
• Service Contingency Risk: Vesting is also contingent on Inderjit Kaul continuing to provide services under a consulting agreement dated November 14, 2025, introducing a dependency on this ongoing relationship.
• Market Risk: The ultimate value of the options, even if vested, depends on the market price of Minerva Neurosciences' common stock exceeding the $3.98 exercise price at the time of exercise.

Future Outlook

The future outlook for a significant portion of the director's compensation is directly tied to the successful outcome of the Phase 3 confirmatory trial of roluperidone in schizophrenia, specifically achieving the primary endpoint and demonstrating safety data.

Industry Context

It is common practice in the biotechnology and pharmaceutical industries to tie executive and director compensation, particularly equity grants, to the achievement of critical clinical trial milestones. This aligns the interests of leadership with the company's scientific and commercial progress, which is often driven by drug development success.

Comparison to Industry Standards

• The practice of granting stock options to directors as part of their compensation is standard across industries, including biotech.
• Tying a significant portion of option vesting to specific clinical trial outcomes (e.g., Phase 3 success for roluperidone) is a common and appropriate mechanism in the biopharmaceutical sector to incentivize performance and align interests with shareholder value creation, given the high-risk, high-reward nature of drug development.

Related Party Transactions

• The vesting of the granted stock options is contingent on Inderjit Kaul continuing to provide services pursuant to a consulting agreement dated November 14, 2025.

Stakeholder Impact

• Shareholders: The performance-based vesting structure aims to align the director's incentives with shareholder value creation, particularly through the successful advancement of the roluperidone clinical program.
• Employees: While not directly mentioned, successful clinical trials could positively impact employee morale and the company's overall prospects.

Next Steps

• Public announcement of statistically significant primary endpoint achievement from the Phase 3 confirmatory trial of roluperidone in schizophrenia (12-week timepoint).
• Public announcement of safety data from the 40-week relapse assessment phase of the roluperidone trial.

Key Dates

Keywords

Minerva Neurosciences, NERV, Stock Option, Director Compensation, SEC Form 4, Roluperidone, Schizophrenia, Clinical Trial, Phase 3, Equity Grant